Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02403895 · ClinicalTrials.gov registry record · Phase 2
AZD2014 and Weekly Paclitaxel in Squamous NSCLC
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02403895 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 11 participants.
The verdict
NCT02403895, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)
Interventions
- DRUG paclitaxel
- DRUG Open-label AZD2014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-04-15 |
| Est. Completion | 2016-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02403895
The ClinicalTrials.gov registry entry for NCT02403895 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT02403895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02403895 about?
NCT02403895 is a clinical study titled "AZD2014 and Weekly Paclitaxel in Squamous NSCLC". Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)
What is the current status of trial NCT02403895?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-04-15. Estimated completion is 2016-12-29.
What interventions are being tested in trial NCT02403895?
The interventions under investigation include: paclitaxel (DRUG), Open-label AZD2014 (DRUG).
Who is sponsoring clinical trial NCT02403895?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.